Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study
Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, Moyses HE, Calder PC, Byrne CD, WELCOME Study
Hepatology (Baltimore, Md.) · 236 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute for Health and Care Research
- Gobierno
- National Institute for Health Research (NIHR)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2014-07-05 · Hepatology · vol. 60 · número 4 · págs. 1211–1221
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 311 citas · más que el 100% de estudios similares · 30.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 35 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Alcohol Consumption and Health Effects
- Palabras clave
- non-alcoholic fatty liver disease, eicosapentaenoic acid, docosahexaenoic acid, omega-3 fatty acids, liver fat, liver fibrosis, medication adherence
- MeSH
- erythrocytes, humans, liver cirrhosis, docosahexaenoic acids, eicosapentaenoic acid, gastrointestinal agents, magnetic resonance spectroscopy, double-blind method, adult, middle aged, female, male, non-alcoholic fatty liver disease
23 autores
- Eleonora Scorletti🇬🇧National Health Service; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; NIHR Southampton Respiratory Biomedical Research Unit; University of Southampton
- Lokpal S. Bhatia🇬🇧National Health Service; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; NIHR Southampton Respiratory Biomedical Research Unit; University of Southampton
- Keith G. McCormick🇬🇧University of Southampton
- Geraldine Clough🇬🇧University of Southampton
- Kathryn L. Nash🇬🇧University Hospital Southampton NHS Foundation Trust
- Leanne Hodson🇬🇧University of Oxford; Oxford Centre for Diabetes, Endocrinology and Metabolism
- Helen E. Moyses🇬🇧National Health Service; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; NIHR Southampton Respiratory Biomedical Research Unit; University of Southampton
- Philip C. Calder🇬🇧National Health Service; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; NIHR Southampton Respiratory Biomedical Research Unit; University of Southampton
- Christopher D. Byrne🇬🇧 · autor de correspondenciaNational Health Service; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; NIHR Southampton Respiratory Biomedical Research Unit; University of Southampton
- Nick Sheron
- Mark Wright
- Nick P. Curzen
- Dhrubo Rakhit
- Charles Peebles
- Angela Darekar
- Alison M. Fletcher
- Adrian Calvin Bateman
- ELIZABETH S. WILLIAMS
- Richard Aspinall
- Andrew J. Fowell
- Tristan Richardson
- J. S.W. Li Voon Chong
- Ma’en Al-Mrayat
Resumen
El texto original del estudio, en el idioma en que se publicó.
There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes and cardiovascular disease. We tested whether 15-18 months treatment with docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA) (Omacor/Lovaza) (4 g/day) decreased liver fat and improved two histologically-validated liver fibrosis biomarker scores (primary outcomes). Patients with NAFLD were randomised in a double blind placebo-controlled trial [DHA+EPA(n=51), placebo(n=52)]. We quantified liver fat percentage (%) by magnetic resonance spectroscopy in three liver zones. We measured liver fibrosis using two validated scores. We tested adherence to the intervention (Omacor group) and contamination (with DHA and EPA) (placebo group) by measuring erythrocyte percentage DHA and EPA enrichment (gas chromatography). We undertook multivariable linear regression to test effects of: a) DHA+EPA treatment (ITT analyses) and b) erythrocyte DHA and EPA enrichment (secondary analysis). Median (IQR) baseline and end of study liver fat% were 21.7 (19.3) and 19.7 (18.0) (placebo), and 23.0 (36.2) and 16.3 (22.0), (DHA+EPA). In the fully adjusted regression model there was a trend towards improvement in liver fat% with DHA+EPA treatment (β=-3.64 (95%CI -8.0,0.8); p=0.1) but there was evidence of contamination in the placebo group and variable adherence to the intervention in the Omacor group. Further regression analysis showed that DHA enrichment was independently associated with a decrease in liver fat% (for each 1% enrichment, β=-1.70 (95%CI -2.9,-0.5); p=0.007). No improvement in the fibrosis scores occurred. Conclusion. Erythrocyte DHA enrichment with DHA+EPA treatment is linearly associated with decreased liver fat%. Substantial decreases in liver fat% can be achieved with high percentage erythrocyte DHA enrichment in NAFLD. (Hepatology 2014;).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.